Cargando…
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies
PURPOSE: This study determined the efficacy of low-dose gemcitabine combined with programmed death-1 (PD-1) inhibitors for treating multiple malignancies, providing a cost-effective and safe treatment option. STUDY DESIGN: This study included 61 patients with advanced solid tumors treated with low-d...
Autores principales: | Huang, Hao, Peng, Ling, Zhang, Bicheng, Till, Brian G., Yang, Yonghao, Zhang, Xiaojie, Zhao, Lingdi, Fu, Xiaomin, Li, Tiepeng, Han, Lu, Qin, Peng, Chen, Lin, Yan, Xiang, Liu, Yang, Wang, Wenkang, Ye, Zhenlong, Li, Hongle, Gao, Quanli, Wang, Zibing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328170/ https://www.ncbi.nlm.nih.gov/pubmed/35911715 http://dx.doi.org/10.3389/fimmu.2022.882172 |
Ejemplares similares
-
Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021) -
Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020) -
Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021) -
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
por: Zhao, Lingdi, et al.
Publicado: (2019) -
Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)